News & Updates
Filter by Specialty:

Is pembrolizumab-lenvatinib effective in recurrent endometrial cancer?
05 Sep 2023
Combination treatment with pembrolizumab and lenvatinib appears to be a better option for patients with recurrent endometrial cancer (REC) or advanced endometrial cancer (AEC) with a platinum-free interval (PFI) of <6 months, suggests a recent study.
Is pembrolizumab-lenvatinib effective in recurrent endometrial cancer?
05 Sep 2023
RT may be omitted after breast-conserving surgery in T1N0, grade 1/2, luminal A breast cancer
04 Sep 2023
byChristina Lau
Radiotherapy (RT) may be omitted in women ≥55 years of age with T1N0, grade 1 or 2, luminal A breast cancer who have been treated with breast-conserving surgery and endocrine therapy, due to the very low risk of 5-year local recurrence reported in a recent prospective cohort study.